| Literature DB >> 35514725 |
Julieth Tatiana Román1, Carlos Alberto Fuenmayor2, Carlos Mario Zuluaga Dominguez3, Dianney Clavijo-Grimaldo4, Martha Acosta5, Javier Eduardo García-Castañeda1, Ricardo Fierro-Medina1, Zuly Jenny Rivera-Monroy1.
Abstract
Electrospinning technology is useful for making ultrafine drug-eluting fibers for the clinical treatment of wounds. We show the incorporation of an antimicrobial LfcinB-derived peptide into Pullulan nanofibers. The palindromic peptide LfcinB (21-25)Pal: RWQWRWQWR was synthesized, purified, and characterized by means of the RP-HPLC and MALDI-TOF MS methods. The peptide's antibacterial activity against the E. coli ATCC 25922 strain was evaluated, and the peptide LfcinB (20-25)Pal exhibited significant antibacterial activity. Nanofibers were obtained by electrospinning a Pullulan or Pullulan-LfcinB (21-25)Pal solution. The obtained nanofibers were characterized via microscopy (AFM and SEM) and RP-HPLC chromatography. The peptide incorporation efficiency was 31%. The Pullulan-LfcinB (21-25)Pal nanofibers were soluble in water, and the peptide was liberated immediately. The Pullulan-LfcinB (21-25)Pal nanofibers exhibited the same antibacterial activity against E. coli strain as the free peptide LfcinB (21-25)Pal. The results suggest that Pullulan-LfcinB (21-25)Pal nanofibers could be considered for designing and developing antibacterial wound dressings. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35514725 PMCID: PMC9065569 DOI: 10.1039/c9ra03643a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Chromatographic characterization of the peptide and membranes. Peptide LfcinB (21–25)Pal (A) crude, (B) pure; (C) Pullulan-LfcinB (21–25)Pal membrane and (D) Pullulan membrane (control).
Fig. 2Membrane characterization. (A) Pullulan-LfcinB (21–25)Pal membrane photography. Membranes were observed under UV radiation at 254 nm: (B) Pullulan-LfcinB (21–25)Pal, and (C) Pullulan membranes.
Fig. 3AFM membrane. (A) Pullulan-LfcinB (21–25)Pal and (B) Pullulan membranes. (Right) membrane 3D projection; (left) membrane topographic profile.
Fig. 4Nanofiber characterization via SEM. (A)–(C) Pullulan-LfcinB (21–25)Pal nanofibers. (D)–(F) Pullulan nanofibers.
Fig. 5Frequency histogram of nanofiber diameter distribution. (A) Pullulan nanofibers; (B) Pullulan-LfcinB (21–25)Pal nanofibers. The ANOVA indicates that there is a significant difference between the diameter of the Pullulan nanofibers and that of the Pullulan-LfcinB (21–25)Pal nanofibers, (n = 100).
Fig. 6Membrane antibacterial activity. Determination of MBC of Pullulan-LfcinB (21–25)Pal nanofibers and the peptide LfcinB (21–25)Pal (control). Bacterial growth inhibition of the E. coli strain treated with (A) peptide LfcinB (21–25)Pal and (B) Pullulan-LfcinB (21–25)Pal nanofibers. (n = 2).
| Peptide | MS | RP-HPLC analysis | Antimicrobial activity CMI/CMB | ||
|---|---|---|---|---|---|
| Theoretical | Experimental |
|
|
| |
| LfcinB (21–25)Pal | 1485.75 | 1485.12 | 5.9 | 97 |
|
| Pullulan-LfcinB (21–25)Pal | — | — | 5.9 | NA |
|
Peptide purity was calculated using the percentage of peak area at the chromatographic profile.
| Electrospinning conditions | LfcinB (21–25)Pal concentration (ppm) | Recovery (%) | ||||
|---|---|---|---|---|---|---|
|
| Flow rate (mL h−1) | Recollection time (min) | Solution electrospinning | Nanofiber | ||
| Pullulan-LfcinB (21–25)Pal | 15 | 0.5 | 20 | 13 347 | 1600 | 12 |
| 4100 | 31 | |||||